促进慢性阿法西亚中增强和替代通信诱导的语言恢复 (PAIL-RcA):理论构建,方法,协议和治疗资源
Aimee Dietz1, Chitrali R Mamlekar2, Michelle K Hart3
1Department of Communication Sciences & Disorders, University of South Florida, Tampa.
American journal of speech-language pathology
|April 4, 2025
概括
本教程指导临床医生使用增强型和替代性沟通 (AAC) 来帮助阿法西亚 (PWA) 患者的语言恢复. 它介绍了小说促进慢性失言症 (PAIL-RcA) 治疗中AAC诱导的语言恢复.
科学领域:
- 神经科学是一个神经科学.
- 语音语言病理学 语音语言病理学
背景情况:
- 失言症通常会导致沟通中断,并阻碍语言恢复.
- 增强型和替代性沟通 (AAC) 可以支持患有失言症 (PWA) 的个人.
- 神经可塑性原则对于有效的沟通康复至关重要.
研究的目的:
- 为临床医生提供实施AAC作为双重用途工具的实用指南.
- 解释AAC如何同时解决通信缺陷并促进PWA中的语言恢复.
- 介绍一种新的治疗方法,即在慢性失言症中促进AAC诱导的语言恢复 (PAIL-RcA),以及其在神经可塑性方面的理论基础.
主要方法:
- 一步一步地概述PAIL-RcA治疗方案.
- 提供基本的实施资源:数据表,提示层次,家庭手册和快速指南.
- 专注于一种新的治疗方法,用于修复失语症.
主要成果:
- PAIL-RcA是以理论驱动和手动化AAC治疗的方式呈现出来的.
- 该疗法是可行的临床实施使用自由可用的资源.
- 展示了PWA对AAC的一种新方法.
结论:
- PAIL-RcA为临床医生提供了一种结构化的方法,可以在PWA中利用AAC进行通信支持和语言恢复.
- 该处理可适应各种AAC系统和通信功能.
- 鼓励探索AAC在神经可塑性驱动的失言症康复中的作用.
相关概念视频
01:27Language and Cognition
301
Language serves as a bridge between ideas and communication, influencing how individuals perceive and interact with the world. Psychologists have long debated whether language shapes thought or vice versa. This discussion gained grip with Edward Sapir and Benjamin Lee Whorf in the 1940s, who proposed that language determines thought, a concept known as linguistic determinism. They suggested that the vocabulary and structure of a language influence how its speakers think and perceive reality.
301
01:25Long-term Potentiation
2.7K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when...
Hebbian LTP
LTP can occur when...
2.7K
01:22Alzheimer's Disease: Treatment
137
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
137